Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

Trastuzumab is a monoclonal antibody used in oncotherapy to treat HER2-positive tumors including breast and other cancers. As an adverse effect, trastuzumab elevates the risk of heart failure ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...